ArticleBiomaterials2011
The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.
Article in Biomaterials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 142 citations in OpenAlex.
- A self-assembled protein nanocage as a universal influenza vaccine induces enhanced broadly cross-reactive immunity.Biomaterials · 2026Article
- Enhanced immunogenicity of the rabies virus glycoprotein fused to a dendritic cell-targeting peptide.Scientific reports · 2026Article
- Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy.Biomaterials research · 2025Review
- Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering.Immuno-oncology technology · 2024Review
- Efferocytosis in dendritic cells: an overlooked immunoregulatory process.Frontiers in immunology · 2024Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.Frontiers in immunology · 2023Review
- A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles.NPJ vaccines · 2022Article
- Critical parameters for design and development of multivalent nanoconstructs: recent trends.Drug delivery and translational research · 2022Review
- Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Embracing nanomaterials' interactions with the innate immune system.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Peptide-based supramolecular vaccine systems.Acta biomaterialia · 2021Review
- Nanoparticles for generating antigen-specific T cells for immunotherapy.Seminars in immunology · 2021Review
- Localized hydrogel delivery of dendritic cells for attenuation of multiple sclerosis in a murine model.Journal of biomedical materials research. Part A · 2021Article
- Biocompatibility of nanomaterials and their immunological properties.Biomedical materials (Bristol, England) · 2021Review
- Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.Frontiers in immunology · 2021Review
- Macrophage imaging and subset analysis using single-cell RNA sequencing.Nanotheranostics · 2021Article
- Review
- DEC-205 receptor-mediated long-circling nanoliposome as an antigen andDrug delivery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Dendritic-cell (DC) targeted antigen delivery systems hold promise for enhancing vaccine efficacy and delivery of therapeutics. However, it is not known how the number and density of targeting ligands on such systems may affect DC function and subsequent T cell response. We modified the surface of biodegradable nanoparticles loaded with antigen with different densities of the mAb to the DC lectin DEC-205 receptor and assessed changes in the cytokine response of DCs and T cells. DEC-205 targeted nanoparticles unexpectedly induced a differential cytokine response that depended on the density of ligands on the surface. Strikingly, nanoparticle surface density of DEC-205 mAb increased the amount of anti-inflammatory, IL-10, produced by DCs and T cells. Boosting mice with DEC-205 targeted OVA-nanoparticles after immunization with an antigen in CFA induced a similar pattern of IL-10 response. The correlation between DC production of IL-10 as a function of the density of anti-DEC-205 is shown to be due to cross-linking of the DEC-205 receptor. Cross-linking also increased DC expression of the scavenger receptor CD36, and blockade of CD36 largely abrogated the IL-10 response. Our studies highlight the importance of target ligand density in the design of vaccine delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.